Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21244030 | 0.86 | MAPT (0.55) | MAPTHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244046 | 0.86 | MAPT (0.49) | MAPTHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244039 | 0.77 | MAPT (0.46) | MAPTHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244042 | 0.75 | ALDH1A1 (0.52) | MAPTHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244051 | 0.75 | MCOLN3 (0.55) | MAPTKMT2AALDH1A1MEN1L3MBTL1 | |
| SCHEMBL21244038 | 0.74 | ALDH1A1 (0.54) | MAPTHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244034 | 0.74 | L3MBTL1 (0.53) | MAPTHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244031 | 0.73 | MCOLN3 (0.52) | MAPTKMT2AALDH1A1MEN1L3MBTL1 | |
| SCHEMBL23570183 | 0.72 | MEN1 (0.41) | MAPTKMT2AALDH1A1MEN1SLC40A1 | |
| SCHEMBL21261364 | 0.72 | MALT1 (0.49) | MAPTHTTALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | claimed |
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | TRPM5, TRPM2, TRPM4 | MAPT 577/4885HTT 531/4885KMT2A 2449/4885 |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | TRPM5, TRPM2, TRPM4 | MAPT 577/4885HTT 531/4885KMT2A 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.